
MKI-1
CAS No. 1190277-80-5
MKI-1( —— )
Catalog No. M35458 CAS No. 1190277-80-5
MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 122 | Get Quote |
![]() ![]() |
5MG | 187 | Get Quote |
![]() ![]() |
10MG | 302 | Get Quote |
![]() ![]() |
25MG | 495 | Get Quote |
![]() ![]() |
50MG | 802 | Get Quote |
![]() ![]() |
100MG | 1197 | Get Quote |
![]() ![]() |
500MG | 2394 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMKI-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM).
-
DescriptionMKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
-
In VitroMKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells.MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation.MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.Western Blot Analysis Cell Line:MCF7 and T47D cells.Concentration:5-20 μM. Incubation Time:24 h.Result:Inhibited the phosphorylation of ENSA in MCF7 and T47D cells.Significantly inhibited the phosphorylation of ENSA in mitotic cells.
-
In VivoMKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.Animal Model:Five-week-old female BALB/c nude mice (BT549 cells).Dosage:50 mg/kg.Administration:Twice per week by intraperitoneal (i.p.) injection.Result:Reduced tumor growth.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1190277-80-5
-
Formula Weight302.33
-
Molecular FormulaC18H14N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (826.91 mM; Ultrasonic )
-
SMILESO=C(Nc1nc2ccccc2[nH]1)c1cccc(c1)-n1cccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10:571601.?
molnova catalog



related products
-
Deruxtecan
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
-
EGF Receptor Substra...
EGF Receptor Substrate 2 (Phospho-Tyr5) is a biologically active peptide derived from an autophosphorylation site (Tyr992) of EGFR.
-
Sepin-1
Sepin-1 is a noncompetitive inhibitor of separase with an IC50 of 14.8 μM. Sepin-1 can inhibit the growth of breast cancer xenograft tumors in mice and human cancer cell lines by inhibiting cell proliferation and inducing apoptosis.